solanezumab
12/28/2016 / By Ethan Huff
Big pharma: Eli Lilly stock erases 6 years of dividends after failed drug trial
What investors had hoped would build into yet another 2.68 percent dividend yield for pharmaceutical behemoth Eli Lilly has turned into a massive financial letdown after trials of solanezumab, a supposedly promising experimental drug for Alzheimer’s disease and other forms of dementia, showed less than favorable efficacy in the latest clinical trials. Reports indicate that […]
1 of 1

Popular Posts

Medicine.News is a fact-based public education website published by Medicine News Features, LLC.

All content copyright © 2018 by Medicine News Features, LLC.

Contact Us with Tips or Corrections

All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.